Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (KCT0012645) titled 'Phase 2 Study of Transarterial Radioembolization in Combination with Chemoimmunotherapy in Patients with Advanced Biliary Tract Cancer with Liver-Dominant Disease' on Sept. 18.
Study Type: Interventional Study
Study Design:
Primary Purpose : Treatment, Intervention Model : Single Group, Blinding/Masking : Open, Allocation : Not Applicable
Primary Sponsor: Asan Medical Center
Condition:
Neoplasms
Intervention:
Procedure/Surgery : Chemoimmunotherapy (every 3 weeks, Cycles 1-8):
Gemcitabine 1,000 mg/m² administered intravenously over 30 minutes on Days 1 and 8 of each cycle.
Cisplatin 25 mg/m² administ...